Stealth BioTherapeutics (Stealth BioTherapeutics) Retained Earnings : $0.00 Mil (As of Mar. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Stealth BioTherapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Stealth BioTherapeutics's retained earnings for the quarter that ended in Mar. 2022 was $0.00 Mil.

Stealth BioTherapeutics's quarterly retained earnings declined from Sep. 2021 ($0.00 Mil) to Dec. 2021 ($-607.98 Mil) but then increased from Dec. 2021 ($-607.98 Mil) to Mar. 2022 ($0.00 Mil).

Stealth BioTherapeutics's annual retained earnings declined from Dec. 2019 ($-498.00 Mil) to Dec. 2020 ($-555.45 Mil) and declined from Dec. 2020 ($-555.45 Mil) to Dec. 2021 ($-607.98 Mil).

Stealth BioTherapeutics Retained Earnings Historical Data

The historical data trend for Stealth BioTherapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stealth BioTherapeutics Retained Earnings Chart

Stealth BioTherapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Retained Earnings

Get a 7-Day Free Trial

-329.56

-426.27

-498.00

-555.45

-607.98

Stealth BioTherapeutics Quarterly Data
	Dec16	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Retained Earnings	Get a 7-Day Free Trial															-	-581.55	-	-607.98	-

Stealth BioTherapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Stealth BioTherapeutics (NAS:MITO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Stealth BioTherapeutics (Stealth BioTherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stealth BioTherapeutics Corp (NAS:MITO) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Intertrust Corporate Services (Cayman) Limited, One Nexus way, Camana Bay, Grand Cayman, CYM, KY1-9005

Website

https://www.stealthbt.com

Stealth BioTherapeutics Corp is a clinical-stage biotechnology company. It is focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction.